See more : Colambda Technologies, Inc. (NCRE) Income Statement Analysis – Financial Results
Complete financial analysis of Cynata Therapeutics Limited (CYP.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cynata Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Heian Ceremony Service Co.,Ltd. (2344.T) Income Statement Analysis – Financial Results
- JDE Peet’s N.V. (JDEPF) Income Statement Analysis – Financial Results
- Clovis Oncology, Inc. (C6O.DE) Income Statement Analysis – Financial Results
- United Alloy-Tech Company (3162.TWO) Income Statement Analysis – Financial Results
- YHN Acquisition I Limited Right (YHNAR) Income Statement Analysis – Financial Results
Cynata Therapeutics Limited (CYP.AX)
About Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.32M | 1.65M | 7.77M | 1.55M | 7.01M | 1.31M | 1.38M | 1.75M | 1.10M | 285.58K | 25.06K | 33.96K | 162.45K | 222.94K | 113.88K | 0.00 | 350.57K | 0.00 |
| Cost of Revenue | 0.00 | 279.97K | 279.97K | 279.97K | 280.73K | 279.97K | 279.97K | 279.97K | 280.73K | 0.00 | 0.00 | 8.69K | 521.48K | 389.44K | 339.84K | 10.13K | 330.59K | 0.00 |
| Gross Profit | 2.32M | 1.37M | 7.49M | 1.27M | 6.73M | 1.03M | 1.10M | 1.47M | 818.98K | 285.58K | 25.06K | 25.28K | -359.02K | -166.50K | -225.96K | -10.13K | 19.98K | 0.00 |
| Gross Profit Ratio | 100.00% | 83.08% | 96.40% | 81.89% | 96.00% | 78.60% | 79.64% | 83.99% | 74.47% | 100.00% | 100.00% | 74.42% | -221.00% | -74.68% | -198.42% | 0.00% | 5.70% | 0.00% |
| Research & Development | 8.96M | 12.39M | 8.82M | 3.78M | 5.92M | 5.65M | 3.22M | 3.47M | 4.16M | 1.92M | 502.82K | 90.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 3.18M | 3.99M | 4.22M | 2.47M | 2.63M | 2.45M | 2.46M | 1.62M | 1.84M | 2.49M | 697.19K | 908.59K | 2.47M | 1.84M | 408.56K | 1.15M | 0.00 |
| Selling & Marketing | 0.00 | 56.37K | 65.97K | 269.65K | 472.74K | 581.35K | 176.31K | 114.90K | 130.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.16M | 3.87M | 4.73M | 5.02M | 4.09M | 4.13M | 2.63M | 2.58M | 1.75M | 1.84M | 2.49M | 697.19K | 908.59K | 2.47M | 1.84M | 408.56K | 1.15M | 0.00 |
| Other Expenses | 0.00 | 1.91M | 6.94M | 1.30M | -222.48K | 1.33M | 1.42M | 1.68M | 1.09M | 459.57K | 25.06K | 176.24K | 194.26K | 129.69K | 69.96K | 250.39K | 1.00M | 0.00 |
| Operating Expenses | 11.12M | 16.26M | 6.62M | 8.80M | 10.23M | 9.78M | 5.85M | 6.05M | 5.90M | 4.26M | 3.15M | 873.43K | 1.38M | 2.53M | 1.91M | 1.42M | 1.61M | 0.00 |
| Cost & Expenses | 11.12M | 16.54M | 6.90M | 9.08M | 10.51M | 10.06M | 6.13M | 6.33M | 6.18M | 4.09M | 3.15M | 882.12K | 1.90M | 2.92M | 2.25M | 1.38M | 2.49M | 0.00 |
| Interest Income | 417.71K | 352.87K | 64.75K | 92.30K | 142.35K | 260.55K | 142.93K | 94.23K | 147.68K | 89.31K | 82.70K | 37.06K | 7.42K | 8.19K | 25.85K | 76.17K | 104.03K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 981.00 | 1.91K | 8.62K | 10.62K | 11.89K | 3.79K | 0.00 |
| Depreciation & Amortization | 279.97K | 279.97K | 279.97K | 279.97K | 280.73K | 279.97K | 279.97K | 279.97K | 280.73K | 447.95K | 208.00 | -66.56K | 413.39K | 9.95K | 3.02K | 4.52K | 5.58K | 0.00 |
| EBITDA | -9.95M | -15.65M | -6.00M | -8.80M | -5.87M | -9.50M | -5.61M | -6.02M | -5.59M | -3.55M | -3.12M | -914.72K | -1.17M | -2.55M | -2.10M | -1.43M | -2.03M | 0.00 |
| EBITDA Ratio | -429.70% | -983.04% | -85.20% | -569.22% | -145.93% | -747.48% | -425.49% | -346.09% | -536.57% | -1,335.16% | -12,559.70% | -2,693.20% | -693.75% | -1,142.22% | -1,846.49% | 0.00% | -421.43% | 0.00% |
| Operating Income | -8.81M | -16.54M | -6.90M | -9.08M | -10.51M | -10.06M | -6.13M | -6.33M | -6.18M | -3.98M | -3.12M | -848.16K | -1.74M | -2.69M | -2.13M | -1.38M | -2.14M | 0.00 |
| Operating Income Ratio | -380.37% | -999.96% | -88.80% | -587.33% | -149.93% | -768.88% | -445.85% | -362.09% | -562.10% | -1,392.01% | -12,460.53% | -2,497.23% | -1,072.36% | -1,208.53% | -1,871.84% | 0.00% | -609.04% | 0.00% |
| Total Other Income/Expenses | -3.25M | 610.71K | 622.45K | 1.39M | 4.36M | 280.43K | 236.20K | 30.15K | 309.42K | 374.89K | -650.77K | -67.54K | 199.77K | 129.26K | 15.51K | -74.37K | 100.23K | 0.00 |
| Income Before Tax | -12.06M | -15.93M | -6.28M | -9.08M | -6.15M | -9.78M | -5.89M | -6.30M | -5.87M | -3.71M | -3.04M | -915.70K | -1.54M | -2.56M | -2.12M | -1.10M | -1.49M | 0.00 |
| Income Before Tax Ratio | -520.82% | -963.05% | -80.79% | -587.35% | -87.71% | -747.44% | -428.67% | -360.37% | -533.96% | -1,299.82% | -12,130.51% | -2,696.09% | -949.39% | -1,150.54% | -1,858.22% | 0.00% | -424.10% | 0.00% |
| Income Tax Expense | -2.32M | -1.65M | -832.68K | -1.39M | -2.51M | -1.31M | -1.33M | -1.75M | -932.58K | -89.31K | -82.70K | -36.08K | 196.17K | 138.31K | 10.62K | -77.87K | 104.03K | 0.00 |
| Net Income | -9.74M | -14.28M | -5.45M | -7.69M | -3.64M | -8.47M | -4.57M | -4.55M | -4.94M | -3.71M | -3.04M | -915.70K | -1.54M | -2.56M | -2.12M | -1.10M | -1.49M | 0.00 |
| Net Income Ratio | -420.82% | -863.05% | -70.08% | -497.38% | -51.90% | -647.44% | -332.05% | -260.37% | -449.16% | -1,299.82% | -12,130.51% | -2,696.09% | -949.39% | -1,150.54% | -1,858.22% | 0.00% | -424.10% | 0.00% |
| EPS | -0.05 | -0.10 | -0.04 | -0.06 | -0.03 | -0.08 | -0.05 | -0.06 | -0.07 | -0.06 | -0.07 | -0.04 | -0.16 | -0.50 | -0.55 | -0.32 | -0.44 | 0.00 |
| EPS Diluted | -0.05 | -0.10 | -0.04 | -0.06 | -0.03 | -0.08 | -0.05 | -0.06 | -0.07 | -0.06 | -0.07 | -0.04 | -0.16 | -0.50 | -0.55 | -0.32 | -0.44 | 0.00 |
| Weighted Avg Shares Out | 179.63M | 145.09M | 143.28M | 130.43M | 104.82M | 100.21M | 90.88M | 80.30M | 72.66M | 60.80M | 45.08M | 23.54M | 9.55M | 5.10M | 3.85M | 3.40M | 3.40M | 3.43M |
| Weighted Avg Shares Out (Dil) | 179.63M | 145.09M | 143.28M | 130.43M | 104.82M | 100.21M | 90.88M | 80.30M | 72.66M | 60.80M | 45.08M | 23.61M | 9.55M | 5.10M | 3.85M | 3.40M | 3.40M | 3.43M |
Source: https://incomestatements.info
Category: Stock Reports